Celgene shines with key haematology pipeline

Celgene, ahead of the BMS merger completion, presented nearly 70 company-sponsored, global alliance and investigator-initiated clinical studies evaluating Celgene’s investigational and approved therapies at last week’s American Society of Hematology (ASH) Annual Meeting.

“Celgene has a deep and ongoing commitment to innovative research and development in treatments for serious blood disorders, with the potential to transform patient outcomes,” said Alise Reicin, M.D., President, Global Clinical Development for Celgene.

In leukemia and lymphoma, highlighted studies included safety and efficacy results from the pivotal TRANSCEND NHL-001 study of an investigational CD-19 targeted chimeric antigen receptor (CAR) T cell therapy lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell non-Hodgkin lymphoma. Additional liso-cel data from three ongoing studies evaluated the use of the therapy in an outpatient setting, as well as in transplant noneligible patients with relapsed/refractory large B-cell non-Hodgkin lymphoma (PILOT) and in patients with relapsed/refractory chronic lymphocytic leukemia (TRANSCEND CLL-004).

Celgene’s Liso-cel would be a potential CAR-T competitor to Novartis’ Kymriah and Gilead’s Yescarta.

In multiple myeloma, other notable investigational cell therapy abstracts included the first phase 1 clinical data from the bi-specific T-Cell Engager (TCE) CC-93269 and updated phase 1 clinical data from CAR T program, bb21217, both targeting the B-cell maturation antigen (BCMA) in relapsed/refractory disease.

Several abstracts focussed on data in myeloid diseases including longer-term response data from the phase 3 MEDALIST study of luspatercept to treat anaemia in patients with IPSS-R very low-, low-, or intermediate-risk myelodysplastic syndromes with ring sideroblasts who require red-blood-cell (RBC) transfusions were presented.

Additionally, the first data from a phase 2 study of luspatercept in myelofibrosis-associated anemia, results from a study of fedratinib in myelofibrosis patients with low platelet counts, and the first data from CELMoD agent CC-90009, a GSPT1 degrader in relapsed or refractory acute myeloid leukemia (AML) were presented.

You may also like Where credibility and trust go, clinicians follow. Download whitepaper.

Register FREE to access Health Industry Hub’s e-news bulletin; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and key stakeholders.